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ABSTRACT
Despite many efforts by the research community, Alzheimer's dis-
ease (AD) is still an incurable neurodegenerative condition that
affects an estimated 44million individualsworldwide and this figure
is expected to increase to 135 million by the year 2050. As the
research community currently reflects on previous endeavours,
it is essential that we maximize the use of existing knowledge
to inform future trials in the field. This article describes the devel-
opment of a systematically identified data set relating to over 300
interventions tested in over 10,000 animals. The data set includes
cohort-level information for six structural outcomes and six beha-
vioural assessments. We encourage others to use this dataset to
inform the design of future animal experiments modelling AD
and to promote effective translation to human health.
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Introduction
Alzheimer's disease (AD) is an incurable neurodegenerative
condition that affects an estimated 44 million individuals
worldwide. This figure is expected to increase to 135million
by the year 2050,1 placing increasing social and economic
strain on society in the years ahead.2 The societal costs of
AD have been estimated to be US$604 billion per year,3
with the burden of care commonly falling on the shoulders
of familymembers, impacting on communities and society as
a whole.
Currently, symptomatic relief can be achieved for some
patients using acetylcholinesterase inhibitors ormemantine,
but these are not suitable or effective option for all patients
at all stages. There is therefore a pressing need both for
interventions capable of providing greater symptomatic
relief, and for disease-modifying interventions therapies that
might slow, or halt or even reverse, the progression of the
condition.
Substantial efforts have beenmade in preclinical science in
order to identify candidate clinical treatments. Much focus
for disease-modifying therapy has concentrated on targets
identified by the amyloid hypothesis including active and pas-
sive immunization strategies (e.g. AN-179, Bapineuzumab)
and gamma secretase inhibitors (e.g. Semagacestat, Taren-
flurbil and Avagecestat).4,5
Following the identification of familial AD and those
mutated genes responsible, transgenic mouse models have
been designed to recapture aspects of AD in vivo for two
decades. The first transgenic mouse model was engineered
in 19956 where the overexpression of a mutated APP
(V717F mutation driven by the platelet-derived growth
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factor promoter) produced a phenotype of amyloid plaques
and neuronal loss. Subsequently, there has been an array of
models produced, includingmodels basedon the expression
of transgenic presenilin (PS)7; or both APP and PS each with
specific AD like pathologies alongside behavioural deficits.8
Collectively, such work culminated in crossing APP, PS and
Tau lines to produce a tripe transgenic model (3xTgAD),
capable of capturing; tau neurofibrillary tangles, aggressive
amyloid plaques and cognitive deficits.9 The success regard-
ing the development of transgenic mouse models has
encouraged extensive testing of candidate intervention stra-
tegies before reaching the clinical trial stage.10 Both beha-
vioural end points (e.g. paradigms such as the Morris
water maze11) and pathological end points (e.g. enzyme-
linked immunosorbent assay for amyloid beta levels,
immunohistochemistry for plaques) can be quantified and
efficacy determined by comparing control and treatment
groups.
The prospect of testing candidate intervention strategies
in animal models capable of capturing aspects of AD pro-
vides opportunities both to demonstrate efficacy in vivo
and to investigate molecular mechanisms. While transgenic
mousemodels have certainly advancedour understanding of
AD, their utility in developing new treatments has been less
certain; Zahs and Ashe10 showed that while over 300 inter-
ventions had been tested in the Tg2576 mouse, none had
met with clinical success. Indeed, no novel clinical treat-
ments have emerged in AD despite over a decade of testing
therapeutics in these transgenic animals.
There are many plausible reasons for translational failure
in AD,12 one of which is that animal transgenic studies have
overestimated the reported efficacy. If this were true, it
would be essential that we understand better the internal
validity (e.g. sample size calculations, blinding and randomi-
zation) and external validity (e.g. are we testing interven-
tions in conditions representative of the clinical setting) of
such experiments. The impact of these factors in a given field
of research can be identified through systematic review, and
these findings disseminated to the wider scientific commu-
nity to inform improvements in research practice. Subse-
quent meta-analysis can also be performed, with the
caveat that however systematically constructed a data set
is unlikely to include all experimental data; some experi-
ments will have been published after the search was per-
formed and there is also likely to be at least some
publication bias and selective outcome reporting bias. Nev-
ertheless, by making this resource available to the commu-
nitywe hope to empowerADresearchers by allowing to set
their research plans and research findings in the context of
what is already known.
Here we have conducted a systematic review of trans-
genic mouse studies testing the efficacy of candidate drugs
in transgenic models of AD. We have extracted data from
these studies for meta-analysis, the results of which will
be presented elsewhere. To allow others to benefit from
these datawe are nowmaking these available to the scientific
community as a whole. Of the many possible uses, we con-
sider this data set will be of most immediate use to others
planning preclinical AD studies (particularly to inform sam-
ple size calculations) or clinical trials of candidate drugs
included in this review. Those interested in using
these data to empirically guide future research can find fur-
ther guidance on the analyses of datasets such as these
in Vesterinen et al.13 and an example of the specific applica-
tion of these techniques to RCT design can be found in a
description of the MS SMART drug repurposing trial in mul-
tiple sclerosis.14 We envisage that the development of
machine learning text mining tools will allow this database
to be updated in the future, and as those tools evolve it
may be possible for such databases to be updated in
real time.
Methods
Studies in animalmodels of ADwere identified from1995 to
Jan 2009 in Pubmed, EMBASE and ISI Web of knowledge
with the search terms [“targeted deletion” OR “overex-
pression” OR “knock out” OR “vector” OR “transgenic”]
AND [“dementia” OR “tau” OR “mild cognitive impair-
ment” OR “Alzheimer's disease”] with the search limited
to animals using the filters available in those databases.
The searches were taken from 1995 as this year coincides
with the productionof the first transgenicADmousemodel.
The searchwas conducted in January 2009. Theprotocol for
this systematic review was defined in advance, and was
amended in Feb 2011 (hierarchy for deciding which cohort
to be used as a control group) andMarch 2011 (definition of
method of calculating area under the curve for Morris
Water Maze acquisition phase).
Inclusion Criteria
Publications were included that tested interventions using
any amyloid-, tau- or PS-based transgenic mouse model
of AD.
Exclusion Criteria
Geneticmanipulations surplus to those required to produce
symptoms of the condition were excluded as with genetic
treatments if intervention took place before birth (i.e. gene
knock-outs or knock-ins). We excluded studies where
more than one treatment was administered. For the
MWM, reversal task behaviour nor time in opposite or adja-
cent quadrants were extracted.
Quality Score
Publications identifiedwereassessedagainst a five-point study
quality checklist adapted from those previously described
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in the “Good Laboratory Practice Guidelines” for stroke
modelling.15 These items included a statement regarding
(1) randomallocation togroup, (2) blindedassessmentofout-
come, (3) sample size calculation, (4) compliance with animal
welfare legislation and (5) declaring a conflict of interest. One
point was awarded for each criterion reported.
Results
Our systematic search identified 427 publications testing
interventions in transgenic mouse models of AD. These
publications described 357 interventions and 55 transgenic
models representing 11,118 animals and 838 experiments.
All extracted data are available through Figshare (see Refer-
encing section for web address).
We organized extracted data into a hierarchy of
three principal areas: publication level details, outcome
level details and additional specific attributes of individual
outcomes (see Figure 1). For publication level details,
see Table 1 and Figure 2. For Outcome level details, see
Tables 2 and 3 and Figure 3.
O U T C O M E L E V E L D E T A I L S
For experimental outcome measures, we extracted over
4,000 individual outcome measure comparisons where a
control groupwas compared to that of the treatment group.
We connected these to the publication level using a one-to-
many relationship and thus could recordmultiple outcomes
for individual studies. Structural outcomeswere particularly
prevalent with publications three times more likely to
report this compared to behavioural outcomes.
For some structural outcomes, it was of interest
to extract further information than the basic outcome
measure level data. For example, for plaque burden
Figure 1. Overall structure of recorded information. Information
was organized across publication level and outcomes with a one to
many relationship. For selected outcomes, further informationwas
also extracted regarding the methodology of the individual
experiments (see later).
Table 1. The organization of publication level information. These 12 field codes (A1 to A12) are used to record information regarding the
publication as a whole such as information specifically regarding the author or overall methodological approaches and study quality items.
See text for more details
Item
Field
code Description Notes
Unique ID A1 Primary key Automatically
generated number
Year A2 Year of publication Numerical entry
Author A3 Primary author Text (lookup table)
Anaesthetic used A4 Anaesthetic used at the time of sacrifice Text (lookup table)
Background strain A5 Detail regarding the background strain of the mice Text (lookup table)
Transgene A6 Specific transgenic mutations, or knock-out used Text (lookup table)
Type of publication A7 Description of whether publication is a full publication or an
abstract
Publication/abstract
Blinded assessment of outcome A8 Reporting in publication that studies were blinded Y/N
Random allocation to group A9 Reporting in publication that animals were randomly allocated to
treatment groups
Y/N
Sample size calculation A10 Reporting in publication of how the sample size of the study
population was statistically identified
Y/N
Compliance with animal welfare
legislation
A11 Reporting of compliance with any animal welfare legislation Y/N
Statement regarding potential
conflicts of interest
A12 Reporting of a conflict of interest statement Y/N
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there were three commonly used staining techniques used:
immunohistochemistry, congo red andThioflavin S and such
details were recorded attached to the outcome meas-
ure level.
For cellular infiltrates, we recorded whether outcomes
represented astrocytosis or microgliosis and for tau we
recorded whether data represented phospho tau (and spe-
cific phosphorylation site) or overall tau levels. Likewise, we
Figure 2. Screenshot of publication level entry form. This form is used to record information regarding the publication as a whole.
Information included specifically relates to details of the author, year or overall methodological approaches and study quality items.
See Table 1 for details.
Table 2. The organization of outcome level information. These 22 field codes (B1 to B22) are used to record more specific information
regarding individual experiments. These data include variables essential tometa-analysis including themean variance and number of animals
in each group. Alongside these details are data concerning the specific methodology of the experiment including the drug, dose, dose units,
route of drug administration and details regarding the age at which interventions are administered and outcomes are assessed
Item
Field
code Description Notes
Outcome measure B1 Specific outcome measure of interest (e.g. plaque pathology, tau or
neurodegeneration)
Text (lookup table)
Publication ID B2 Unique primary key for each study within a given publication (e.g. each drug
examined within a publication would be assigned a new publication ID)
Automatically
generated number
Outcome measure ID B3 Unique primary key for individual outcomes Automatically
generated number
Group letter B4 Unique primary key for individual cohorts. Combined with publication ID
identifies where specific cohorts exists
Text (lookup table)
Number of animals in
control group
B5 Most conservative estimate of control animals used Numerical entry
Number of animals in
treatment group
B6 Most conservative estimate of treatment animals used Numerical entry
Number of wild type
animals
B7 Most conservative estimate of wild type animals used Numerical entry
Mean in control group B8 Mean in control group Numerical entry
Variance in control
group
B9 Variance in control group (standard deviation or standard error of the mean) Numerical entry
(continued overleaf )
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Table 2 (continued)
Item
Field
code Description Notes
Mean in treatment group B10 Mean in treatment group Numerical entry
Variance in treatment
group
B11 Variance in treatment group (standard deviation or standard error of themean) Numerical entry
Mean in wild type group B12 Mean in wild type group Numerical entry
Variance in wild type
group
B13 Variance in wild type group (standard deviation or standard error of the mean) Numerical entry
Age at intervention
administration
B14 Age in days of animals at the time of first intervention administration Numerical entry
Age at outcome
assessment
B15 Age in days of animals at the time of outcome assessment Numerical entry
Dose B16 Drug dose used Numerical entry
Dose units B17 Drug dose units Numerical entry
Route of drug delivery B18 Route of drug into body Text (lookup table)
Number of treatment
groups per control
B19 How many time a control group serves in study Numerical entry
Drug B20 Intervention tested Text (lookup table)
Sex B21 Sex of animal used Text (lookup table)
Animal type B22 Type of animal used Text (lookup table)
Table 3. The organization of specific outcome attributes information. These field codes (C1 toC12) provide further context on the details
regarding individual techniques or experiments. For example, for behavioural experiments that use the Morris water maze, specific
information regarding the methodological set up can be useful to experimenters for planning future experiments (see C1 to C5)
Outcome and item
Field
code Description Notes
Morris water maze
Size of pool C1 Diameter of the pool used in metres Numerical entry
Water temperature C2 Average temperature of the water used in degrees Celsius Numerical entry
Number of days
training
C3 Number of total days training (can be different from acquisition curve points) Numerical entry
Training sessions per
day
C4 Number of acquisition training sessions per day Numerical entry
Time point
(acquisition only)
C5 Specific time point number during acquisition training Numerical entry
Plaque burden
Staining technique
used
C6 Description of whether plaques are stained with immunohistochemical methods,
congo red or Thioflavin S
Text (lookup table)
Amyloid beta 40/42
Solubility C7 Soluble, insoluble or total amyloid measured Text (lookup table)
Tau
Description of tau
entity
C8 Description of whether outcome represents “overall” tau or “phosphorylation
state” of tau
Text (lookup table)
Measurement
technique
C9 Description of tau antibody used Text (lookup table)
Cellular infiltrates
Data type C10 Details of whether data astrocytes or microglia. Text (lookup table)
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extracted information regarding neurodegeneration
according to the specific variable measured.
N E U R O B E H A V I O U R A L O U T C O M E S
We identified six key neurobehavioral outcome measures;
the training (acquisition phase) and the test (probe phase) of
the Morris water maze, Radial arm water maze, fear condi-
tioning, the Y maze and T maze.
For the Morris water maze, we were able to extract
a number of paradigm-specific methodological attributes.
For example, we extracted data recording the number
of days training, the number of training sessions per
day, the temperature of the water in the Morris water
maze, the diameter of the pool and the time delay
between the end of the acquisition phase and the probe
“test” phase assessment. In addition, for acquisition time
points we measured all data points and associated
errors.
Referencing
Other investigators are welcome to use, with attribution, the
data reposited on Figshare http://plos.figshare.com/articles/
Interventions_tested_in_preclinical_studies_using_transgen-
ic_mouse_models_of_AD/1185428. This should be refer-
enced through reference to this publication.
Conflict of Interest
The authors declare that there are no conflicts of
interest.
Figure 3. Screenshot of outcome level entry form. This form is used to record information variables essential to meta-analysis including
the mean variance and number of animals in each group. Alongside these details are data concerning the specific methodology of the
experiment including the drug, dose, dose units, route of drug administration and details regarding the age at which interventions are
administered and outcomes are assessed. See Table 2 for details.
Table 3 (continued)
Outcome and item
Field
code Description Notes
Neurodegeneration
Outcome type C11 Description of whether neurodegeneration outcome might be considered a
"direct" or "indirect" measure
Text (lookup table)
Outcome measure
specificity
C12 Specific methodology used to assess neurodegeneration Text (lookup table)
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